GlassScriptPhysician profile
John Gelly
NPI 1851381164
$3,964.49
in general payments reported to CMS, 2019-2025
31 companies · $19.33 in 2025
The $19.33 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $1,290 · 2021: $876 · 2022: $509 · 2023: $16.64 · 2024: $13.97 · 2025: $19.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $49.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $49.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $743.36 | 2019-2022 | |
| Allergan, INC. | $423.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $375.97 | 2019-2022 | |
| Abbvie INC. | $324.11 | 2019-2022 | |
| Astellas Pharma US INC | $263.12 | 2019-2021 | |
| Novo Nordisk INC | $258.70 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.79 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $154.87 | 2019-2022 | |
| Lilly USA, LLC | $151.47 | 2019-2022 | |
| Amarin Pharma, INC. | $140.30 | 2019-2021 | |
| Pfizer INC. | $139.01 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.16 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $94.38 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $93.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $74.48 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.10 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $51.85 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.62 | 2022 | |
| Abbott Laboratories | $34.82 | 2022-2025 | Freestyle Libre 3 |
| Eisai INC. | $33.01 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $31.06 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $30.61 | 2023-2024 | Contrave |
| Biohaven Pharmaceutical Holding Company LTD. | $21.61 | 2022 | |
| Radius Health, INC. | $19.86 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.00 | 2022 | |
| Lundbeck LLC | $16.34 | 2020 | |
| Esperion Therapeutics, INC. | $16.00 | 2020 | |
| Medtronic Vascular, INC. | $14.61 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.64 | 2020 | |
| Gilead Sciences, INC. | $12.18 | 2020 | |
| Aytu Biopharma, INC. | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.